M
Martin Ridderstråle
Researcher at Lund University
Publications - 124
Citations - 22978
Martin Ridderstråle is an academic researcher from Lund University. The author has contributed to research in topics: Type 2 diabetes & Insulin. The author has an hindex of 35, co-authored 120 publications receiving 20479 citations. Previous affiliations of Martin Ridderstråle include Steno Diabetes Center & Scania AB.
Papers
More filters
Journal ArticleDOI
Characterization of a naturally occurring mutation (L107I) in the HNF1 alpha (MODY3) gene.
Camilla Cervin,Marju Orho-Melander,Martin Ridderstråle,M Lehto,Sebastian Barg,Leif Groop,Corrado M. Cilio +6 more
TL;DR: The results suggest that the L107I substitution represents a MODY3 mutation which impairs beta-cell function by a loss-of-function mechanism.
Journal ArticleDOI
Regulation of skeletal muscle PPAR delta mRNA expression in twins.
Emma Nilsson,Pernille Poulsen,Marketa Sjögren,Charlotte Ling,Martin Ridderstråle,Leif Groop,Allan Vaag +6 more
TL;DR: Evidence is provided that mRNA expression of PPARδ in human skeletal muscle is under genetic control but also influenced by factors such as age, birth weight and central adiposity, as well as other factors including glucose and lipid metabolism.
Journal ArticleDOI
Impact of a multifactorial treatment programme on clinical outcomes and cardiovascular risk estimates: a retrospective cohort study from a specialised diabetes centre in Denmark.
TL;DR: The data support that short-term multifactorial treatment of patients with glycaemic dysregulation in a specialist outpatient setting is both achievable and effective, and associated with a clinically meaningful improvement in CVD risk.
Journal ArticleDOI
Processes Underlying Glycemic Deterioration in Type 2 Diabetes: An IMI DIRECT Study
Roberto Bizzotto,Christopher Jennison,Angus G. Jones,Azra Kurbasic,Andrea Tura,Gwen Kennedy,Jimmy D. Bell,E. Louise Thomas,Gary Frost,Rebeca Eriksen,Robert W. Koivula,Robert W. Koivula,Soren Brage,Jane Kaye,Jane Kaye,Andrew T. Hattersley,Alison Heggie,Donna McEvoy,Leen M 't Hart,Leen M 't Hart,Joline W. Beulens,Petra J. M. Elders,Petra B. Musholt,Martin Ridderstråle,Tue H. Hansen,Kristine H. Allin,Torben Hansen,Henrik Vestergaard,Agnete T. Lundgaard,Agnete T. Lundgaard,Henrik S. Thomsen,Federico De Masi,Konstantinos D. Tsirigos,Konstantinos D. Tsirigos,Søren Brunak,Søren Brunak,Ana Viñuela,Ana Viñuela,Anubha Mahajan,Timothy J. McDonald,Tarja Kokkola,Ian M Forgie,Giuseppe N. Giordano,Imre Pavo,Hartmut Ruetten,Emmanouil T. Dermitzakis,Mark I. McCarthy,Mark I. McCarthy,Oluf Pedersen,Jochen M. Schwenk,Jerzy Adamski,Jerzy Adamski,Paul W. Franks,Mark Walker,Ewan R. Pearson,Andrea Mari +55 more
TL;DR: Deteriorating insulin sensitivity and β-cell function, increasing insulin clearance, high visceral or liver fat, and worsening of the lipid profile are the crucial factors mediating glycemic deterioration of patients with T2D in the initial phase of the disease.
Journal ArticleDOI
Treatment Modality–Dependent Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes: Danish Adult Diabetes Database Study
Sari Hoshina,Gregers S. Andersen,Marit E. Jørgensen,Marit E. Jørgensen,Martin Ridderstråle,Martin Ridderstråle,Dorte Vistisen,Henrik U. Andersen +7 more
TL;DR: Delivery of CSII in large diabetes clinics with sufficient support and patient education may ensure that CSII treatment does not lead to an increased risk of DKA.